|
Name |
Mollicellin G
|
| Molecular Formula | C21H20O6 | |
| IUPAC Name* |
3,9-dihydroxy-1,7-dimethyl-2-(3-methylbut-2-enyl)-6-oxobenzo[b][1,4]benzodioxepine-10-carbaldehyde
|
|
| SMILES |
CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=C(C(=C3)O)CC=C(C)C)C)C=O)O
|
|
| InChI |
InChI=1S/C21H20O6/c1-10(2)5-6-13-12(4)19-17(8-16(13)24)26-21(25)18-11(3)7-15(23)14(9-22)20(18)27-19/h5,7-9,23-24H,6H2,1-4H3
|
|
| InChIKey |
YCVIERNKAZOGOU-UHFFFAOYSA-N
|
|
| Synonyms |
Mollicellin G; 68455-08-3; M39FZR61JT; 11H-Dibenzo(b,e)(1,4)dioxepin-4-carboxaldehyde, 3,8-dihydroxy-1,6-dimethyl-7-(3-methyl-2-butenyl)-11-oxo-; UNII-M39FZR61JT; DTXSID30218570; 3,9-dihydroxy-1,7-dimethyl-2-(3-methylbut-2-enyl)-6-oxobenzo[b][1,4]benzodioxepine-10-carbaldehyde; Q27283427; 11H-DIBENZO(B,E)(1,4)DIOXEPIN-4-CARBOXALDEHYDE, 3,8-DIHYDROXY-1,6-DIMETHYL-7-(3-METHYL-2-BUTEN-1-YL)-11-OXO-
|
|
| CAS | 68455-08-3 | |
| PubChem CID | 129296 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 368.4 | ALogp: | 4.9 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 93.1 | Aromatic Rings: | 3 |
| Heavy Atoms: | 27 | QED Weighted: | 0.347 |
| Caco-2 Permeability: | -4.938 | MDCK Permeability: | 0.00001940 |
| Pgp-inhibitor: | 0.022 | Pgp-substrate: | 0.025 |
| Human Intestinal Absorption (HIA): | 0.071 | 20% Bioavailability (F20%): | 0.895 |
| 30% Bioavailability (F30%): | 0.002 |
| Blood-Brain-Barrier Penetration (BBB): | 0.02 | Plasma Protein Binding (PPB): | 99.66% |
| Volume Distribution (VD): | 0.553 | Fu: | 1.35% |
| CYP1A2-inhibitor: | 0.792 | CYP1A2-substrate: | 0.156 |
| CYP2C19-inhibitor: | 0.821 | CYP2C19-substrate: | 0.072 |
| CYP2C9-inhibitor: | 0.781 | CYP2C9-substrate: | 0.801 |
| CYP2D6-inhibitor: | 0.092 | CYP2D6-substrate: | 0.246 |
| CYP3A4-inhibitor: | 0.294 | CYP3A4-substrate: | 0.127 |
| Clearance (CL): | 8.51 | Half-life (T1/2): | 0.283 |
| hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.026 |
| Drug-inuced Liver Injury (DILI): | 0.24 | AMES Toxicity: | 0.086 |
| Rat Oral Acute Toxicity: | 0.986 | Maximum Recommended Daily Dose: | 0.947 |
| Skin Sensitization: | 0.819 | Carcinogencity: | 0.149 |
| Eye Corrosion: | 0.006 | Eye Irritation: | 0.949 |
| Respiratory Toxicity: | 0.764 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000921 | ![]() |
0.947 | D0Q0PR | ![]() |
0.255 | ||
| ENC002489 | ![]() |
0.738 | D0FA2O | ![]() |
0.237 | ||
| ENC004153 | ![]() |
0.689 | D04FBR | ![]() |
0.221 | ||
| ENC005959 | ![]() |
0.644 | D0O6KE | ![]() |
0.220 | ||
| ENC002677 | ![]() |
0.627 | D07MGA | ![]() |
0.218 | ||
| ENC002676 | ![]() |
0.622 | D02PMO | ![]() |
0.214 | ||
| ENC000631 | ![]() |
0.561 | D06GCK | ![]() |
0.214 | ||
| ENC004156 | ![]() |
0.547 | D0Z4XW | ![]() |
0.212 | ||
| ENC000919 | ![]() |
0.536 | D0WY9N | ![]() |
0.211 | ||
| ENC002703 | ![]() |
0.517 | D0K8KX | ![]() |
0.209 | ||